Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lower back pain
Biotech
Spine BioPharma misses primary endpoint in back pain phase 3
With the biotech pinning the flop on a “very high sham control response,” management plans to meet with the FDA to discuss a potential path to market.
Nick Paul Taylor
Aug 1, 2025 10:24am
Mainstay Medical merits $125M for back pain neuromod implant
Feb 28, 2024 12:07pm
FDA expands OK for Boston Sci WaveWriter spinal cord stimulators
Feb 6, 2024 12:28pm
Boston Sci bids $850M for nerve ablation tech maker Relievant
Sep 19, 2023 10:43am
FDA approves Abbott's spinal cord stimulators for back pain
May 16, 2023 12:51pm
AppliedVR nets FDA’s first approval for VR back pain device
Nov 17, 2021 10:00am
